These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Sample size estimations for MRI-monitored trials of MS comparing new vs standard treatments.
    Author: Sormani MP, Rovaris M, Bagnato F, Molyneux P, Bruzzi P, Pozzilli C, Miller DH, Comi G, Filippi M.
    Journal: Neurology; 2001 Nov 27; 57(10):1883-5. PubMed ID: 11723280.
    Abstract:
    The authors estimated the sample sizes needed for exploratory trials of MS assessing the efficacy of new treatments in reducing the number of new enhancing lesions vs those of interferon-beta or glatiramer acetate. The sample sizes per arm ranged from 868 (effect: 20%) to 94 (effect: 50%) for patients with relapsing-remitting MS and from 2,484 (effect: 20%) to 361 (effect: 50%) for patients with secondary progressive MS. In MS, exploratory trials of new vs available therapies require large numbers of patients, even when MR end-points are used.
    [Abstract] [Full Text] [Related] [New Search]